Sage, Biogen drug meets goal in postpartum depression study

Sage Therapeutics and partner Biogen plan to next year ask the Food and Drug Administration for approval of their experimental antidepressant zuranolone in postpartum depression after reporting positive results from a late-stage clinical trial of the drug on Wednesday.